In mice with prostate tumors, adding degarelix to anti-PD1 and cryoablation doubled the time to accelerated growth in untreated tumors.
In plain wordsIn mice, adding degarelix to anti-PD1 and cryoablation doubled the time to accelerated growth in untreated tumors.
- Peptide
- Degarelix
- Outcome
- IncreaseTime to accelerated distant tumor growth
- Study
mousen: not reported in source
FVB/NJ mice with bilateral Myc-Cap tumors- Comparator
- Anti-PD1 therapy and cryoablation without ADT
- Outcome group
- Tumor growth · Cancer
- Studied dose
- Dose not stated
Measurements
- P value
- 0.0021 NA
- time to accelerated growth
Source sentences
Addition of ADT to anti-PD1 therapy and cryoablation doubled the time to accelerated growth in the untreated tumors (p = 0.0021)
2 context sentences(design, population, supporting numbers)
FVB/NJ mice were injected subcutaneously into each flank with either 1 × 106 or 0.2 × 106 isogenic hormone sensitive Myc-Cap cells to establish synchronous grafts.
Mice were treated with four intraperitoneal injections of anti-PD-1 (10 mg/kg), anti-CTLA-4 (1 mg/kg), or isotype control antibody with or without adjuvant cryoablation of the larger tumor graft and with or without neo-adjuvant androgen deprivation with degarelix (ADT).